Navigation Links
Wyeth Announces Launch of Own Generic Version of PROTONIX
Date:1/29/2008

sed on the limited record before it, Wyeth and Nycomed were not entitled to the extraordinary relief of a preliminary injunction. Trial is expected in the second half of 2008.

About Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, we note that the impact of generic pantoprazole tablets on sales of PROTONIX cannot be predicted with certainty and will depend upon market and competitive conditions, the outcome of future proceedings in this litigation and other factors, many of which are beyond our control. We and our partner Nycomed may not be able to uphold the validity of the PROTONIX patent, recover our lost profits and other damages resulting from infringing sales and/or obtain a permanent injunction against further sales of generic pantoprazole. Other risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products, including with respect to our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Wyeth Declares Common and Preferred Stock Dividends
2. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
3. Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
4. Wyeth Sets Webcast and Conference Call for 2007 Fourth Quarter and Full Year Earnings
5. SmartOps Enterprise Inventory Optimization Software Licensed by Wyeth
6. Wyeth Receives Honors at the 2007 Scrip Awards
7. Wyeth Announces Executive Promotions
8. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
9. Wyeth to Present at the Credit Suisse First Boston Healthcare Conference
10. Wyeth Consumer Healthcare Announces the Availability of Centrum Cardio and New Formula Centrum Products
11. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 24, 2014 Dr. Vu Ho, ... expansion of his practice and med-spa with the addition ... growing list of cosmetic treatments and services. , “Silk ... the skin,” says Dr. Ho. “As a result it ... as wrinkles, sun spots, discolorations or blemishes.” , Similar ...
(Date:12/24/2014)... 24, 2014 Mike Billings , ... with Derek Fenwick, PT, MBA, GCS, Director of ... stem from the passing of the Improving Medicare ... In this taping of the Infinicast, the two leaders ... the Social Security Act to standardize post-acute assessment data ...
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay ... call for giving the cholesterol-lowering drugs known as statins to ... These new standards bring the association in line with the ... recommend giving low- or high-dose statins to all people at ... agree that the decision to start a statin should be ...
(Date:12/24/2014)... 2014 The 2014 Market Research ... and in-depth research report on COC industry. For ... information, including its definition, classification, application, industry chain ... This report also presents product specification, manufacturing process, ... by regions, technology and applications. Analysis also covers ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... study supports raising age for screening, which U.S. is pondering, ... adds evidence to support a growing movement to raise the ... detect cervical cancer. , In England, the recommended age at ... recently raised to 25. In the United States, however, ...
... Researchers have identified MEK4 as a pro-invasion protein and the ... according to a new study published online July 28 in ... Li Xu, M.D., Ph.D., and Raymond C. Bergan, M.D., of ... colleagues investigated the target for genistein in prostate cancer cells ...
... , , , , ... APFC ) today announced that it will release its ... Gibson, Chairman and Chief Executive Officer, invites you to participate in ... , The teleconference will be held Tuesday, August 4, 2009 ...
... , NEW YORK, July 28 Finding time to treat ... during stressful times. Here,s more on a how you can do ... Listen to this report from Kellogg,s at: , ... access video, audio, text, graphics and photos for free and unrestricted use ...
... , , , ... Eleven innovative veterinary students from around the world were ... animals and wildlife. The students, whose projects were funded through ... posters of their results at MAF,s annual meeting in June. ...
... , , BETHESDA, Md., July 28 Hanger ... of $193.5 million for the quarter ended June 30, 2009, an ... prior year. Net income increased $2.0 million, or 25.4%, to ... last year. Earnings per share for the second quarter of 2009 ...
Cached Medicine News:Health News:Teens May Not Benefit from Pap Tests 2Health News:Teens May Not Benefit from Pap Tests 3Health News:American Pacific to Release Financial Results and Hold Fiscal 2009 Third Quarter Investor Teleconference 2Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 2Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 3Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 4Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 2Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 3Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 4Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 5Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 6Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 7Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 8Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 9
(Date:12/24/2014)... BARBARA, Calif. , Dec. 23, 2014 In ... Junior Doctors, Association of Sierra Leone , ... Sierra Leone for the treatment of local health ... While a new dedicated Ebola care center was constructed ... virus, the facility is not available for local Sierra Leonean ...
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) ... Blood Glucose Market" report to their offering. ... market insight focuses on the developments in the self-monitoring ... . Reimbursement analysis and the effects of competitive ... than 73 SMBG meters have been performed, based on ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... -- Global Information, Inc. (GII) is pleased to announce ... Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017" by ... The Insulin Delivery Devices Market is Set to Grow ... 2017 GlobalData estimated the global insulin ...
... N.C., Jan. 13, 2012  Facing patent cliffs and shrinking ... either through in-licensing deals or M&A activities - as ... sound strategy, but a difficult one to effectively put ... a business is fraught with potential pitfalls. With 2012 ...
Cached Medicine Technology:Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 2Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 3Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 4Excellence Services Program Delivers a Road Map to Successfully Guide the Pharmaceutical Industry Through the New Alliance Landscape 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: